Controversy and significance of vascular mimicry in malignant tumors
-
摘要: 血管拟态(VM)指实体肿瘤内部由肿瘤细胞独立形成的, 具有供氧及血液循环功能的管状结构。自1999年由美国俄亥俄州州立大学Hendrix教授提出后，其功能、结构及所提示的临床意义均备受争议。尽管如此，学术界众多研究还是倾向于这种管状结构符合血管的形态及功能特征。由于VM是模拟血管内皮细胞形成血管的过程，众多参与内皮细胞依赖性血管生成的信号在VM形成中的作用也相应被关注及研究。本文对近年来VM研究过程中的相关争议问题进行综述。Abstract: Vascular mimicry (VM) refers to a tubular structure with oxygen supply and blood circulation functions, which is independently formed by tumor cells in solid tumors. Since it was proposed by Professor Hendrix of Ohio State University in 1999, its function, structure and clinical significance have been controversial. Nevertheless, many academic studies still tend to believe that this tubular structure conforms to the morphological and functional characteristics of blood vessels. Because VM simulates the process of vascular endothelial cells forming blood vessels, the role of many signals involved in endothelial cell-dependent angiogenesis in VM formation has also been concerned and studied. This paper summarized the relevant controversial issues in the recent VM researches.
-
-
[1] SHIN S U, CHO H M, DAS R, et al. Inhibition of vasculogenic mimicry and angiogenesis by an anti-EGFR IgG1-human endostatin-P125A fusion protein reduces triple negative breast cancer metastases[J]. Cells, 2021, 10(11): 2904. doi: 10.3390/cells10112904
[2] YOU B S, SUN Y, LUO J, et al. Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR[J]. Oncogene, 2021, 40(9): 1674-1689. doi: 10.1038/s41388-020-01616-1
[3] WILLIAMSON S C, METCALF R L, TRAPANI F, et al. Vasculogenic mimicry in small cell lung cancer[J]. Nat Commun, 2016, 7: 13322. doi: 10.1038/ncomms13322
[4] PEZZELLA F, RIBATTI D. Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies[J]. Cancer Rep, 2020: e1318. https://pubmed.ncbi.nlm.nih.gov/33295149/
[5] YANG Z H, SUN B C, ZHAO X L, et al. Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis[J]. Int J Clin Exp Pathol, 2015, 8(4): 4033-4043. https://pubmed.ncbi.nlm.nih.gov/26097591/
[6] LI B M, MAO X P, WANG H, et al. Vasculogenic mimicry in bladder cancer and its association with the aberrant expression of ZEB1[J]. Oncol Lett, 2018, 15(4): 5193-5200. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840607/
[7] SUN B C, QIE S, ZHANG S W, et al. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors[J]. Hum Pathol, 2008, 39(3): 444-451. doi: 10.1016/j.humpath.2007.07.018
[8] SCULLY S, FRANCESCONE R, FAIBISH M, et al. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas[J]. J Neurosci, 2012, 32(37): 12950-12960. doi: 10.1523/JNEUROSCI.2017-12.2012
[9] MANIOTIS A J, CHEN X, GARCIA C, et al. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix[J]. Lab Invest, 2002, 82(8): 1031-1043. doi: 10.1097/01.LAB.0000024362.12721.67
[10] HUJANEN R, ALMAHMOUDI R, KARINEN S, et al. Vasculogenic mimicry: a promising prognosticator in head and neck squamous cell carcinoma and esophageal cancer A systematic review and meta-analysis[J]. Cells, 2020, 9(2): 507. doi: 10.3390/cells9020507
[11] SUN B C, ZHANG S W, ZHAO X L, et al. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas[J]. Int J Oncol, 2004, 25(6): 1609-1614. https://pubmed.ncbi.nlm.nih.gov/15547697/
[12] CHEN L X, HE Y J, SUN S Z, et al. Vasculogenic mimicry is a major feature and novel predictor of poor prognosis in patients with orbital rhabdomyosarcoma[J]. Oncol Lett, 2015, 10(3): 1635-1641. doi: 10.3892/ol.2015.3469
[13] ZHANG F M, LIN H, CAO K Y, et al. Vasculogenic mimicry plays an important role in adrenocortical carcinoma[J]. Int J Urol, 2016, 23(5): 371-377. doi: 10.1111/iju.13070
[14] LV J F, SUN B C, SUN H Z, et al. Significance of vasculogenic mimicry formation in gastric carcinoma[J]. Oncol Res Treat, 2017, 40(1/2): 35-41. https://pubmed.ncbi.nlm.nih.gov/28118629/
[15] HAN G S, LI Y N, CAO Y Q, et al. Overexpression of leptin receptor in human glioblastoma: correlation with vasculogenic mimicry and poor prognosis[J]. Oncotarget, 2017, 8(35): 58163-58171. doi: 10.18632/oncotarget.17344
[16] WANG S Y, KE Y Q, LU G H, et al. Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma[J]. J Neurooncol, 2013, 112(3): 339-345. doi: 10.1007/s11060-013-1077-7
[17] CHEN L, LIN Z X, LIN G S, et al. Classification of microvascular patterns via cluster analysis reveals their prognostic significance in glioblastoma[J]. Hum Pathol, 2015, 46(1): 120-128. doi: 10.1016/j.humpath.2014.10.002
[18] SHIRAKAWA K, KOBAYASHI H, HEIKE Y J, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft[J]. Cancer Res, 2002, 62(2): 560-566. https://pubmed.ncbi.nlm.nih.gov/11809710/
[19] LIU C, HUANG H N, DOÑATE F, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors[J]. Cancer Res, 2002, 62(19): 5470-5475. https://pubmed.ncbi.nlm.nih.gov/12359755/
[20] SUN. A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model[J]. Oncol Rep, 2009, 21(4): 989-994. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2617786/
[21] REN H Y, SHEN J X, MAO X M, et al. Correlation between tumor vasculogenic mimicry and poor prognosis of human digestive cancer patients: a systematic review and meta-analysis[J]. Pathol Oncol Res, 2019, 25(3): 849-858. doi: 10.1007/s12253-018-0496-3
[22] BAJCSY P, LEE S C, LIN A, et al. Three-dimensional volume reconstruction of extracellular matrix proteins in uveal melanoma from fluorescent confocal laser scanning microscope images[J]. J Microsc, 2006, 221(Pt 1): 30-45. https://pubmed.ncbi.nlm.nih.gov/16438687/
[23] ANGARA K, BORIN T F, ARBAB A S. Vascular mimicry: a novel neovascularization mechanism driving anti-angiogenic therapy (AAT) resistance in glioblastoma[J]. Transl Oncol, 2017, 10(4): 650-660. doi: 10.1016/j.tranon.2017.04.007
[24] SOOD A K, SEFTOR E A, FLETCHER M S, et al. Molecular determinants of ovarian cancer plasticity[J]. Am J Pathol, 2001, 158(4): 1279-1288. doi: 10.1016/S0002-9440(10)64079-5
[25] SEFTOR R E, SEFTOR E A, KOSHIKAWA N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma[J]. Cancer Res, 2001, 61(17): 6322-6327. https://pubmed.ncbi.nlm.nih.gov/11522618/
[26] SHARMA N, SEFTOR R E B, SEFTOR E A, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry[J]. Prostate, 2002, 50(3): 189-201. doi: 10.1002/pros.10048
[27] DEMOU Z N. Time-lapse analysis and microdissection of living 3D melanoma cell cultures for genomics and proteomics[J]. Biotechnol Bioeng, 2008, 101(2): 307-316. doi: 10.1002/bit.21899
[28] HESS A R, SEFTOR E A, SEFTOR R E B, et al. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry[J]. Cancer Res, 2003, 63(16): 4757-4762. https://pubmed.ncbi.nlm.nih.gov/12941789/
[29] NOOROLYAI S, SHAJARI N, BAGHBANI E, et al. The relation between PI3K/AKT signalling pathway and cancer[J]. Gene, 2019, 698: 120-128. doi: 10.1016/j.gene.2019.02.076
[30] HESS A R, POSTOVIT L M, MARGARYAN N V, et al. Focal adhesion kinase promotes the aggressive melanoma phenotype[J]. Cancer Res, 2005, 65(21): 9851-9860. doi: 10.1158/0008-5472.CAN-05-2172
[31] LISSITZKY J C, PARRIAUX D, RISTORCELLI E, et al. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro[J]. Cancer Res, 2009, 69(3): 802-809. doi: 10.1158/0008-5472.CAN-08-2391
[32] LU X S, SUN W, GE C Y, et al. Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas[J]. Int J Oncol, 2013, 42(6): 2103-2115. doi: 10.3892/ijo.2013.1897
[33] LIU W B, XU G L, JIA W D, et al. Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma[J]. Med Oncol, 2011, 28(Suppl 1): S228-S238. https://pubmed.ncbi.nlm.nih.gov/20957524/
[34] CHAI D M, BAO Z Q, HU J G, et al. Vasculogenic mimicry and aberrant expression of HIF-lα/E-cad are associated with worse prognosis of esophageal squamous cell carcinoma[J]. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(3): 385-391. doi: 10.1007/s11596-013-1129-4
[35] SEROVA M, TIJERAS-RABALLAND A, DOS SANTOS C, et al. Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib[J]. Oncotarget, 2016, 7(25): 38467-38486. doi: 10.18632/oncotarget.9542
[36] SUN H Z, ZHANG D F, YAO Z, et al. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry[J]. Cancer Biol Ther, 2017, 18(4): 205-213. doi: 10.1080/15384047.2017.1294288
[37] PINTO M P, SOTOMAYOR P, CARRASCO-AVINO G, et al. Escaping antiangiogenic therapy: strategies employed by cancer cells[J]. Int J Mol Sci, 2016, 17(9): 1489. doi: 10.3390/ijms17091489
[38] VASUDEV N S, REYNOLDS A R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions[J]. Angiogenesis, 2014, 17(3): 471-494. doi: 10.1007/s10456-014-9420-y
[39] RUF W, SEFTOR E A, PETROVAN R J, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry[J]. Cancer Res, 2003, 63(17): 5381-5389. https://pubmed.ncbi.nlm.nih.gov/14500372/
[40] DELGADO-BELLIDO D, SERRANO-SAENZ S, FERNÁNDEZ-CORTÉS M, et al. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin[J]. Mol Cancer, 2017, 16(1): 65. doi: 10.1186/s12943-017-0631-x
[41] BREIER G, GROSSER M, REZAEI M. Endothelial cadherins in cancer[J]. Cell Tissue Res, 2014, 355(3): 523-527. doi: 10.1007/s00441-014-1851-7
[42] HENDRIX M J C, SEFTOR E A, HESS A R, et al. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma[J]. Nat Rev Cancer, 2003, 3(6): 411-421. doi: 10.1038/nrc1092
[43] KIRSCHMANN D A, SEFTOR E A, HARDY K M, et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications[J]. Clin Cancer Res, 2012, 18(10): 2726-2732. doi: 10.1158/1078-0432.CCR-11-3237
[44] SEFTOR R E B, HESS A R, SEFTOR E A, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise[J]. Am J Pathol, 2012, 181(4): 1115-1125. doi: 10.1016/j.ajpath.2012.07.013
[45] REIS M, LIEBNER S. Wnt signaling in the vasculature[J]. Exp Cell Res, 2013, 319(9): 1317-1323. doi: 10.1016/j.yexcr.2012.12.023
[46] RIBATTI D, TAMMA R, ANNESE T. Epithelial-mesenchymal transition in cancer: a historical overview[J]. Transl Oncol, 2020, 13(6): 100773. doi: 10.1016/j.tranon.2020.100773
[47] QI L S, SONG W Z, LIU Z Y, et al. Wnt3a promotes the vasculogenic mimicry formation of colon cancer via Wnt/β-catenin signaling[J]. Int J Mol Sci, 2015, 16(8): 18564-18579. doi: 10.3390/ijms160818564
[48] SUN D, SUN B C, LIU T J, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma[J]. J Cell Mol Med, 2013, 17(8): 1038-1047. doi: 10.1111/jcmm.12087
[49] MENG J, SUN B C, ZHAO X L, et al. Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma[J]. Mol Cancer Ther, 2014, 13(12): 3107-3122. doi: 10.1158/1535-7163.MCT-13-1060
计量
- 文章访问数:
- HTML全文浏览量:
- PDF下载量:
下载:
苏公网安备 32100302010246号
